⌘K
t
MYCELX Technologies Corporation announced on 10 April 2025 the grant of share options on 9 April 2025 under its 2011 Omnibus Performance Incentive Plan. Chief Financial Officer Kimberly Slayton and Chief Executive Officer Connie Mixon each received 25,000 share options at an exercise price of US$0.31. These grants were part of wider awards totalling 200,000 options to employees, bringing the aggregate outstanding options to 1,506,668, which represents 6.18% of the company's 24,363,814 issued Common Shares.
| Date | 10 Apr 2025 |
| Time | 07:00:14 |
| Category | Director/PDMR dealings |
| ID | 4808E |
10 April 2025
MYCELX Technologies Corporation
("MYCELX" or the "Company") (AIM: MYX)
Grant of Share Options
The Company announces the grant of share options over the Company's common shares of US$0.025 each ("Common Shares") under the 2011 MYCELX Omnibus Performance Incentive Plan which was extended at the 2019 Annual Meeting (the "Plan").
Details of the awards to a Director and one PDMR on 9 April 2025 together with their current beneficial holdings of Common Shares are presented below:
Grant of Share Options to Chief Financial Officer
|
Name |
Number of share options granted |
Exercise price |
Total number of share options held following this notification |
Total number of share options as % of current issued share capital |
|
|
|
|
|
|
|
Kimberly Slayton |
25,000 |
US$0.31* |
331,667 |
1.36% |
Ms. Slayton holds no Common Shares in the issued capital of the Company.
Grant of Share Options to Chief Executive Officer
|
Name |
Number of share options granted |
Exercise price |
Total number of share options held following this notification |
Total number of share options as % of current issued share capital |
|
|
|
|
|
|
|
Connie Mixon |
25,000 |
US$0.31* |
275,000 |
1.13% |
In addition, following this award, Connie Mixon continues to be interested in 2,931,576 Common Shares, representing 12.03 per cent of the present issued capital of the Company.
The aggregate number of Common Shares held by Ms. Mixon also includes (a) 150,000 shares held by limited liability companies controlled by Ms. Mixon; and (b) 202,646 shares held by or on behalf of Ms. Mixon's children.
The above grants formed part of wider grants of, in aggregate, 200,000 options to employees across the Company, on the same date, representing 0.82% of the current issued share capital.
These share options granted on 9 April 2025 will vest as to 50% on 31 December 2025 and 50% on 31 December 2026, and must be exercised prior to the tenth anniversary of the vesting date, subject to the restrictions on dealing under the Company's share dealing code.
Following the above grants, a total of 1,506,668 share options have been granted to directors, employees and consultants and are currently outstanding, representing 6.18% of the issued share capital of 24,363,814 Common Shares.
*Based on the closing mid-market price of the Company's Common Shares at 8 April 2025, and the closing US/£ exchange rate at that date.
Details of the transactions are reported in the PDMR notifications below:
|
1 |
Details of the person discharging managerial responsibilities / person closely associated
|
||
|
a) |
Name |
Kimberly Slayton |
|
|
2 |
Reason for the notification
|
||
|
a) |
Position/status |
Chief Financial Officer
|
|
|
b) |
Initial notification/Amendment |
Initial Notification
|
|
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||
|
a) |
Name |
MYCELX Technologies Corporation
|
|
|
b) |
LEI |
213800UJZINIK2VD1G48 |
|
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
|
||
|
a) |
Description of the financial instrument, type of instrument |
Grant of options over 25,000 common shares of US$0.025 each.
ISIN: US62847T2024
|
|
|
c) |
Currency |
US$ |
|
|
d) |
Price(s) and volumes(s) |
Price(s) |
Volume(s)
|
|
|
|
US$0.31 |
25,000 |
|
e) |
Aggregated information - Aggregated volume - Price
|
As above |
|
|
f) |
Date of the transaction |
9 April 2025 |
|
|
g) |
Place of the transaction |
N/A (grant of options) |
|
|
1 |
Details of the person discharging managerial responsibilities / person closely associated
|
||
|
a) |
Name |
Connie Mixon |
|
|
2 |
Reason for the notification
|
||
|
a) |
Position/status |
Director and Chief Executive Officer
|
|
|
b) |
Initial notification/Amendment |
Initial Notification
|
|
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||
|
a) |
Name |
MYCELX Technologies Corporation
|
|
|
b) |
LEI |
213800UJZINIK2VD1G48 |
|
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
|
||
|
a) |
Description of the financial instrument, type of instrument |
Grant of options over 25,000 common shares of US$0.025 each.
ISIN: US62847T2024
|
|
|
c) |
Currency |
US$ |
|
|
d) |
Price(s) and volumes(s) |
Price(s) |
Volume(s)
|
|
|
|
US$0.31 |
25,000 |
|
e) |
Aggregated information - Aggregated volume - Price
|
As above |
|
|
f) |
Date of the transaction |
9 April 2025 |
|
|
g) |
Place of the transaction |
N/A (grant of options) |
|
For further information, please contact:
|
MYCELX Technologies Corporation Connie Mixon, CEO Kim Slayton, CFO |
Tel: +1 888 306 6843 |
|
Cavendish Capital Markets Limited (Nominated Adviser and Sole Broker) Giles Balleny / Dan Hodkinson (Corporate Finance) Ondraya Swanson (Corporate Broking) Jasper Berry / Michael Johnson (Sales) |
Tel: +44 20 7220 0500
|
|
Celicourt Communications (Financial PR) Mark Antelme Jimmy Lea Charlie Denley-Myerson |
Tel: +44 20 7770 6424 |